<DOC>
	<DOCNO>NCT00049595</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat stage III stage IV Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens treat patient stage III stage IV Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Comparison Two Combination Chemotherapy Regimens Treating Patients With Stage III Stage IV Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare event-free survival patient stage III IV Hodgkin 's lymphoma treat bleomycin , etoposide , doxorubicin , cyclophosphamide , vincristine , procarbazine , prednisone v doxorubicin , bleomycin , vinblastine , dacarbazine . - Compare complete response , disease-free survival , overall survival patient treat regimen . - Compare quality life patient treat regimen . - Compare occurrence second malignancy patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord International Prognostic Score ( 3 vs 4 ) participate center . Patients randomize 1 2 treatment arm . - Arm I ( BEACOPP ) : Patients receive doxorubicin IV 5 minute cyclophosphamide IV day 1 ; etoposide IV 30 minute day 1-3 ; oral procarbazine day 1-7 ; oral prednisone day 1-14 ; vincristine IV bleomycin IV intramuscularly ( IM ) day 8 . Patients may receive dexamethasone place prednisone . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 9 continue blood count recover pegfilgrastim SC day 9 . Treatment repeat every 22 day 8 course ( 4 course escalate dose follow 4 course baseline dose ) absence disease progression unacceptable toxicity . - Arm II ( ABVD ) : Patients receive doxorubicin IV 5 minute , bleomycin IV IM , vinblastine IV , dacarbazine IV 5-10 minute day 1 15 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . Quality life assess baseline , end therapy , annually 10 year . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 550 patient ( 225 per treatment arm ) accrue study within 5.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma No lymphocyte predominant , nodular type ( nodular paragranuloma ) Clinical stage III IV disease At least 1 bidimensionally measurable target lesion extranodal lesion International Prognostic Score least 3 PATIENT CHARACTERISTICS : Age 16 60 Performance status WHO 02 Life expectancy Not specify Hematopoietic WBC great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic No prior uncontrolled hepatitis B viral infection Bilirubin great 2.5 time normal ( unless due Hodgkin 's lymphoma ) Renal Creatinine great 2.0 mg/dL ( unless due Hodgkin 's lymphoma ) Cardiovascular No severe cardiac disease would limit normal life expectancy preclude study LVEF least 50 % Pulmonary No severe pulmonary disease would limit normal life expectancy preclude study Respiratory function least 30 % Other HIV negative HTLV1 negative No severe active infection No severe neurological metabolic disease would limit normal life expectancy preclude study No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix No psychological , familial , sociological , geographical condition would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Surgery Not specify Other No prior therapy Hodgkin 's lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
</DOC>